These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 15510160)

  • 1. Post-translational modification of p53 in tumorigenesis.
    Bode AM; Dong Z
    Nat Rev Cancer; 2004 Oct; 4(10):793-805. PubMed ID: 15510160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promyelocytic leukemia protein is required for gain of function by mutant p53.
    Haupt S; di Agostino S; Mizrahi I; Alsheich-Bartok O; Voorhoeve M; Damalas A; Blandino G; Haupt Y
    Cancer Res; 2009 Jun; 69(11):4818-26. PubMed ID: 19487292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.
    Hofmann TG; Möller A; Sirma H; Zentgraf H; Taya Y; Dröge W; Will H; Schmitz ML
    Nat Cell Biol; 2002 Jan; 4(1):1-10. PubMed ID: 11740489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of p53 responses by post-translational modifications.
    Xu Y
    Cell Death Differ; 2003 Apr; 10(4):400-3. PubMed ID: 12719715
    [No Abstract]   [Full Text] [Related]  

  • 5. The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain.
    Mellert H; Sykes SM; Murphy ME; McMahon SB
    Cell Cycle; 2007 Jun; 6(11):1304-6. PubMed ID: 17534149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PML regulates p53 stability by sequestering Mdm2 to the nucleolus.
    Bernardi R; Scaglioni PP; Bergmann S; Horn HF; Vousden KH; Pandolfi PP
    Nat Cell Biol; 2004 Jul; 6(7):665-72. PubMed ID: 15195100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras.
    Pearson M; Carbone R; Sebastiani C; Cioce M; Fagioli M; Saito S; Higashimoto Y; Appella E; Minucci S; Pandolfi PP; Pelicci PG
    Nature; 2000 Jul; 406(6792):207-10. PubMed ID: 10910364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.
    Herzer K; Weyer S; Krammer PH; Galle PR; Hofmann TG
    Cancer Res; 2005 Dec; 65(23):10830-7. PubMed ID: 16322229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PML interaction with p53 and its role in apoptosis and replicative senescence.
    Pearson M; Pelicci PG
    Oncogene; 2001 Oct; 20(49):7250-6. PubMed ID: 11704853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation.
    Brooks CL; Gu W
    Curr Opin Cell Biol; 2003 Apr; 15(2):164-71. PubMed ID: 12648672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Regulation of p53 function and promoter selectivity by post-translational modifications].
    Tanaka T
    Seikagaku; 2010 Mar; 82(3):200-9. PubMed ID: 20408452
    [No Abstract]   [Full Text] [Related]  

  • 12. Activation and activities of the p53 tumour suppressor protein.
    Bálint E E; Vousden KH
    Br J Cancer; 2001 Dec; 85(12):1813-23. PubMed ID: 11747320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3.
    Lin J; Tang H; Jin X; Jia G; Hsieh JT
    Oncogene; 2002 May; 21(19):3082-8. PubMed ID: 12082540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?
    Olsson A; Manzl C; Strasser A; Villunger A
    Cell Death Differ; 2007 Sep; 14(9):1561-75. PubMed ID: 17627286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posttranslational modifications involved in the DNA damage response.
    Anderson CW; Appella E; Sakaguchi K
    J Protein Chem; 1998 Aug; 17(6):527. PubMed ID: 9723732
    [No Abstract]   [Full Text] [Related]  

  • 16. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells.
    Kim TK; Lee JS; Oh SY; Jin X; Choi YJ; Lee TH; Lee Eh; Choi YK; You S; Chung YG; Lee JB; DePinho RA; Chin L; Kim H
    Cancer Res; 2007 Dec; 67(23):11133-40. PubMed ID: 18056437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The function of PML in p53-dependent apoptosis.
    Guo A; Salomoni P; Luo J; Shih A; Zhong S; Gu W; Pandolfi PP
    Nat Cell Biol; 2000 Oct; 2(10):730-6. PubMed ID: 11025664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.
    Insinga A; Monestiroli S; Ronzoni S; Carbone R; Pearson M; Pruneri G; Viale G; Appella E; Pelicci P; Minucci S
    EMBO J; 2004 Mar; 23(5):1144-54. PubMed ID: 14976551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct pattern of p53 phosphorylation in human tumors.
    Minamoto T; Buschmann T; Habelhah H; Matusevich E; Tahara H; Boerresen-Dale AL; Harris C; Sidransky D; Ronai Z
    Oncogene; 2001 Jun; 20(26):3341-7. PubMed ID: 11423984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. hADA3 is required for p53 activity.
    Wang T; Kobayashi T; Takimoto R; Denes AE; Snyder EL; el-Deiry WS; Brachmann RK
    EMBO J; 2001 Nov; 20(22):6404-13. PubMed ID: 11707411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.